Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2011

01-09-2011 | Article

UCP2 −866G/A and Ala55Val, and UCP3 −55C/T polymorphisms in association with type 2 diabetes susceptibility: a meta-analysis study

Authors: K. Xu, M. Zhang, D. Cui, Y. Fu, L. Qian, R. Gu, M. Wang, C. Shen, R. Yu, T. Yang

Published in: Diabetologia | Issue 9/2011

Login to get access

Abstract

Aims/hypothesis

A meta-analysis was performed to assess the association between the UCP2 −866G/A, UCP2 Ala55Val and UCP3 −55C/T polymorphisms and type 2 diabetes susceptibility.

Methods

A literature-based search was conducted to identify all relevant studies. The fixed or random effect pooled measure was calculated mainly at the allele level to determine heterogeneity bias among studies. Further analyses were performed that stratified for ethnicity.

Results

We examined 17 publications. Stratified analysis for ethnicity and sensitivity analysis revealed that there was no heterogeneity between studies for these variants. Using an additive model, no significant association of the UCP2 −866G/A polymorphism with type 2 diabetes risk was observed, either in participants of Asian (OR 1.05, 95% CI 0.96, 1.16) or of European (OR 1.03, 95% CI 0.99, 1.07) descent. Neither the UCP2 Ala55Val nor the UCP3 −55C/T polymorphism showed any significant association with type 2 diabetes risk in Europeans (OR 1.04, 95% CI 0.98, 1.09 for Ala55Val; OR 1.04, 95% CI 1.00, 1.09 for −55C/T). In contrast, a statistically significant association was observed for both polymorphisms in participants of Asian descent (OR 1.23, 95% CI 1.12, 1.36 for Ala55Val; OR 1.15, 95% CI 1.03, 1.28 for −55C/T).

Conclusions/interpretation

Our meta-analysis suggests that the UCP2 −866G/A polymorphism is unlikely to be associated with increased type 2 diabetes risk in the populations investigated. In contrast, our results indicate that the UCP2 Ala55Val and UCP3 −55C/T polymorphisms may indeed be risk factors for susceptibility to type 2 diabetes in individuals of Asian descent, but not in individuals of European descent. This conclusion warrants confirmation by further studies.
Appendix
Available only for authorised users
Literature
1.
Dalgaard LT, Pedersen O (2001) Uncoupling proteins: functional characteristics and role in the pathogenesis of obesity and type II diabetes. Diabetologia 44:946–965PubMedCrossRef
2.
Fleury C, Neverova M, Collins S et al (1997) Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet 15:269–272PubMedCrossRef
3.
Solanes G, Vidal-Puig A, Grujic D, Flier JS, Lowell BB (1997) The human uncoupling protein-3 gene. Genomic structure, chromosomal localization, and genetic basis for short and long form transcripts. J Biol Chem 272:25433–25436PubMedCrossRef
4.
Krauss S, Zhang CY, Lowell BB (2005) The mitochondrial uncoupling-protein homologues. Nat Rev Mol Cell Biol 6:248–261PubMedCrossRef
5.
Chan CB, Kashemsant N (2006) Regulation of insulin secretion by uncoupling protein. Biochem Soc Trans 34:802–805PubMedCrossRef
6.
de Souza CT, Araujo EP, Stoppiglia LF et al (2007) Inhibition of UCP2 expression reverses diet-induced diabetes mellitus by effects on both insulin secretion and action. FASEB J 21:1153–1163PubMedCrossRef
7.
Chan CB, DeLeo D, Joseph JW et al (2001) Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action. Diabetes 50:1302–1310PubMedCrossRef
8.
Zhang CY, Baffy G, Perret P et al (2001) Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 105:745–755PubMedCrossRef
9.
Krook A, Digby J, O’Rahilly S, Zierath JR, Wallberg-Henriksson H (1998) Uncoupling protein 3 is reduced in skeletal muscle of NIDDM patients. Diabetes 47:1528–1531PubMedCrossRef
10.
Jia JJ, Zhang X, Ge CR, Jois M (2009) The polymorphisms of UCP2 and UCP3 genes associated with fat metabolism, obesity and diabetes. Obes Rev 10:519–552PubMedCrossRef
11.
Krempler F, Esterbauer H, Weitgasser R et al (2002) A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans. Diabetes 51:3331–3335PubMedCrossRef
12.
Esterbauer H, Schneitler C, Oberkofier H et al (2001) A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 28:178–183PubMedCrossRef
13.
D’Adamo M, Perego L, Cardellini M et al (2004) The −866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of type 2 diabetes. Diabetes 53:1905–1910PubMedCrossRef
14.
Sasahara M, Nishi M, Kawashima H et al (2004) Uncoupling protein 2 promoter polymorphism −866G/A affects its expression in beta-cells and modulates clinical profiles of Japanese type 2 diabetic patients. Diabetes 53:482–485PubMedCrossRef
15.
Sesti G, Cardellini M, Marini MA et al (2003) A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects. Diabetes 52:1280–1283PubMedCrossRef
16.
Astrup A, Toubro S, Dalgaard LT, Urhammer SA, Sorensen TI, Pedersen O (1999) Impact of the v/v 55 polymorphism of the uncoupling protein 2 gene on 24-h energy expenditure and substrate oxidation. Int J Obes Relat Metab Disord 23:1030–1034PubMedCrossRef
17.
Yu X, Jacobs DR, Schreiner PJ, Gross MD, Steffes MW, Fornage M (2005) The uncoupling protein 2 Ala55Val polymorphism is associated with diabetes mellitus: the CARDIA Study. Clin Chem 51:1451–1456PubMedCrossRef
18.
Walder K, Norman RA, Hanson RL et al (1998) Association between uncoupling protein polymorphisms (UCP2-UCP3) and energy metabolism/obesity in Pima Indians. Hum Mol Genet 7:1431–1435PubMedCrossRef
19.
Meirhaeghe A, Amouyel P, Helbecque N et al (2000) An uncoupling protein 3 gene polymorphism associated with a lower risk of developing type II diabetes and with atherogenic lipid profile in a French cohort. Diabetologia 43:1424–1428PubMedCrossRef
20.
Parmar MKB, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834PubMedCrossRef
21.
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef
22.
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta analyses. BMJ 327:557–560PubMedCrossRef
23.
Dupont WD, Plummer WD Jr (1990) Power and sample size calculations. A review and computer program. Control Clin Trials 11:116–128PubMedCrossRef
24.
Wacholder S, Chanock S, Garcia-Closas M, ElGhormli L, Rothman N (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–442PubMedCrossRef
25.
Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25:3443–3457PubMedCrossRef
26.
Wang H, Chu WS, Lu T, Hasstedt SJ, Kern PA, Elbein SC (2004) Uncoupling protein-2 polymorphisms in type 2 diabetes, obesity, and insulin secretion. Am J Physiol Endocrinol Metab 286:E1–E7PubMedCrossRef
27.
Ji Q, Ikegami H, Fujisawa T et al (2004) A common polymorphism of uncoupling protein 2 gene is associated with hypertension. J Hypertens 22:97–102PubMedCrossRef
28.
Bulotta A, Ludovico O, Coco A et al (2005) The common −866G/A polymorphism in the promoter region of the UCP-2 gene is associated with reduced risk of type 2 diabetes in Caucasians from Italy. J Clin Endocrinol Metab 90:1176–1180PubMedCrossRef
29.
Pinelli M, Giacchetti M, Acquaviva F et al (2006) Beta2-adrenergic receptor and UCP3 variants modulate the relationship between age and type 2 diabetes mellitus. BMC Med Genet 7:85PubMedCrossRef
30.
Hsu YH, Niu T, Song Y, Tinker L, Kuller LH, Liu S (2008) Genetic variants in the UCP2-UCP3 gene cluster and risk of diabetes in the women’s health initiative observational study. Diabetes 57:1101–1107PubMedCrossRef
31.
Lee HJ, Ryu HJ, Shin HD et al (2008) Associations between polymorphisms in the mitochondrial uncoupling proteins (UCPs) with T2DM. Clin Chim Acta 398:27–33PubMedCrossRef
32.
Beitelshees AL, Finck BN, Leone TC et al (2010) Interaction between the UCP2 −866G>A polymorphism, diabetes, and beta-blocker use among patients with acute coronary syndromes. Pharmacogenet Genomics 20:231–238PubMed
33.
Heidari J, Akrami SM, Heshmat R, Amiri P, Fakhrzadeh H, Pajouhi M (2010) Association study of the −866G/A UCP2 gene promoter polymorphism with type 2 diabetes and obesity in a Tehran population: a case control study. Arch Iran Med 13:384–390PubMed
34.
Voight BF, Scott LJ, Steinthorsdottir V et al (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42:579–589PubMedCrossRef
35.
Vimaleswaran KS, Radha V, Ghosh S, Majumder PP, Sathyanarayana Rao MR, Mohan V (2011) Uncoupling protein 2 and 3 gene polymorphisms and their association with type 2 diabetes in Asian Indians. Diabetes Technol Ther 13:19–25PubMedCrossRef
36.
Kubota T, Mori H, Tamori Y et al (1998) Molecular screening of uncoupling protein 2 gene in patients with noninsulin-dependent diabetes mellitus or obesity. J Clin Endocrinol Metab 83:2800–2804PubMedCrossRef
37.
Cho YM, Ritchie MD, Moore JH et al (2004) Multifactor-dimensionality reduction shows a two-locus interaction associated with type 2 diabetes mellitus. Diabetologia 47:549–554PubMedCrossRef
38.
Dalgaard LT, Hansen T, Urhammer SA, Drivsholm T, Borch-Johnsen K, Pedersen O (2001) The uncoupling protein 3–55 C>T variant is not associated with Type II diabetes mellitus in Danish subjects. Diabetologia 44:1065–1067PubMedCrossRef
39.
Saxena R, Voight BF, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336PubMedCrossRef
40.
Scott LJ, Mohlke KL, Bonnycastle LL et al (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341–1345PubMedCrossRef
41.
Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661–678CrossRef
42.
Zeggini E, Weedon MN, Lindgren CM et al (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316:1336–1341PubMedCrossRef
43.
Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885PubMedCrossRef
44.
45.
Munafo MR, Flint J (2008) Meta-analysis of genetic association studies. Trends Genet 20:439–444CrossRef
46.
Patsopoulos NA, Evangelou E, Ioannidis JP (2008) Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 37:1148–1157PubMedCrossRef
47.
Crispim D, Fagundes NJ, dos Santos KG et al (2010) Polymorphisms of the UCP2 gene are associated with proliferative diabetic retinopathy in patients with diabetes mellitus. Clin Endocrinol (Oxf) 72:612–619CrossRef
48.
Cheurfa N, Dubois-Laforgue D, Ferrarezi DA et al (2008) The common −866G>A variant in the promoter of UCP2 is associated with decreased risk of coronary artery disease in type 2 diabetic men. Diabetes 57:1063–1068PubMedCrossRef
Metadata
Title
UCP2 −866G/A and Ala55Val, and UCP3 −55C/T polymorphisms in association with type 2 diabetes susceptibility: a meta-analysis study
Authors
K. Xu
M. Zhang
D. Cui
Y. Fu
L. Qian
R. Gu
M. Wang
C. Shen
R. Yu
T. Yang
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2245-y

Other articles of this Issue 9/2011

Diabetologia 9/2011 Go to the issue

Article

Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes

Letter

Prevention strategies for type 2 diabetes should be based on evidence-based medical nutrition data. Reply to Uusitupa M, Lindström J, Tuomilehto J [letter]

Article

Novel hormone-regulated genes in visceral adipose tissue: cloning and identification of proinflammatory cytokine-like mouse and human MEDA-7: implications for obesity, insulin resistance and the metabolic syndrome

Letter

Risk scores for predicting type 2 diabetes: using the optimal tool

Article

Role for inducible cAMP early repressor in promoting pancreatic beta cell dysfunction evoked by oxidative stress in human and rat islets

Commentary

New approaches for the evaluation of renal vascular function in diabetes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits